This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Arch Ophthalmol. 2002;120:648-652.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

Transpupillary thermotherapy (TTT) was introduced by investigators from the Netherlands in 1995 as an alternative treatment for choroidal melanoma.^1-2 Since that time, TTT has been used to treat small choroidal melanomas, and preliminary results indicating that TTT can control small melanomas with follow-up of 5 or more years have been published.^3-4 However, localized retinal destruction, vascular occlusions, and nerve fiber bundle defects are commonly associated with effective treatment of small melanomas with TTT. Despite these observed retinal complications, some investigators have recently reported that TTT, using the same laser intensity to treat choroidal melanoma, may successfully treat occult subfoveal choroidal neovascularizations in patients with age-related macular degeneration without observing deleterious retinal complications.⁵ The encouraging results in pilot studies with TTT in the management of occult choroidal neovascular membranes has led to the development of a multicenter prospective randomized clinical trial (Transpupillary Thermotherapy [TTT] of Occult Subfoveal Choroidal Neovascularization in Patients . . . [Full Text of this Article]

Report of a Case

Histopathologic Findings

Comment

Corrresponding author and reprints: Dennis M. Robertson, MD, Department of Ophthalmology, Mayo Clinic, Rochester, MN 55905 (e-mail: robertson.dennis@mayo.edu).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?